Part of TOTALL’s complete Semaglutide Guide. Medically reviewed by the endocrine and obesity-medicine team at TOTALL Diabetes Hormone Institute, Indore. Last updated August 2026.
Polycystic Ovary Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following an international consensus process in 2026. The new name reflects the fact that the condition affects much more than the ovaries, with important hormonal, metabolic, reproductive, skin and mental-health features. The clinical recommendations have not changed simply because the name has changed, but the terminology now better reflects the condition’s broader biology.
PMOS, fatty liver disease and insulin resistance are often discussed as separate conditions, but they frequently overlap. Understanding that metabolic connection helps explain why semaglutide, a medicine primarily approved for type 2 diabetes and weight management, is increasingly relevant when these problems occur together.
Table of Contents
- 1. Why PMOS, Fatty Liver and Insulin Resistance Are Discussed Together
- 2. Semaglutide and Insulin Resistance: The Core Mechanism
- 3. Semaglutide and PMOS: What the Evidence Actually Supports
- 4. Is Semaglutide Approved for PMOS? Setting Expectations
- 5. Semaglutide and Fatty Liver Disease: A Major Recent Development
- 6. What Semaglutide Does and Doesn’t Fix About Liver Health
- 7. Who With PMOS or Fatty Liver Might Be a Candidate
- 8. How This Fits Into TOTALL’s Broader Approach to Metabolic Disease
- 9. What to Expect If You’re Being Considered for This
- 10. Frequently Asked Questions
- 11. Conclusion
1. Why PMOS, Fatty Liver and Insulin Resistance Are Discussed Together
Polyendocrine Metabolic Ovarian Syndrome (PMOS), formerly known as Polycystic Ovary Syndrome (PCOS), is a complex endocrine and metabolic condition rather than simply an ovarian disorder. Insulin resistance is common in PMOS and can contribute to compensatory increases in insulin levels, which may influence androgen production, ovulatory function and other features of the condition.
Insulin resistance is also strongly associated with metabolic dysfunction-associated steatotic liver disease (MASLD), in which excess fat accumulates in the liver in association with metabolic risk factors. In some people, MASLD progresses to metabolic dysfunction-associated steatohepatitis (MASH), where liver fat is accompanied by inflammation and liver injury and may eventually lead to fibrosis.
Obesity frequently overlaps with these conditions and can worsen metabolic risk, although PMOS and fatty liver disease can occur in people who are not classified as obese by BMI alone. This is particularly relevant when assessing South Asian patients, where metabolic risk can occur at lower BMI levels than in many Western populations.
The important point is that these conditions are connected, but they are not simply three different symptoms of one disease. Each has its own diagnostic criteria, causes, complications and treatment considerations. Their overlap is one reason a broader metabolic assessment can be more useful than treating each finding in isolation.
2. Semaglutide and Insulin Resistance: The Core Mechanism
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Its metabolic effects include increasing glucose-dependent insulin secretion, reducing inappropriate glucagon secretion, slowing gastric emptying and reducing appetite and food intake. The resulting improvement in body weight and glycaemic control can also improve insulin sensitivity.
This matters because insulin sensitivity is influenced by several factors, including body fat, liver fat, physical activity and overall metabolic health. Semaglutide does not simply “switch off” insulin resistance, and the degree of improvement varies between individuals. Some of its metabolic benefits occur alongside weight loss, while other effects are related to the drug’s direct physiological actions.
This is the main biological connection between semaglutide and conditions such as PMOS and fatty liver disease: the medicine can improve several metabolic factors that commonly accompany these conditions, particularly when excess weight, impaired glucose regulation or insulin resistance are present.
3. Semaglutide and PMOS: What the Evidence Actually Supports
In 2026, the condition previously known as PCOS was officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The international guideline has adopted the new terminology while retaining the clinical recommendations developed in the existing evidence base.
Semaglutide is not a PMOS-specific medicine. The current evidence around GLP-1-based treatment in PMOS is primarily concerned with metabolic health, excess weight and related risk factors rather than treating the underlying reproductive condition directly.
For adults with PMOS and higher weight, an anti-obesity medicine such as semaglutide may therefore be considered when it is appropriate under its approved weight-management indication. The international PMOS guideline notes that evidence for anti-obesity medicines in PMOS, particularly for reproductive outcomes, remains limited, and reproductive uses should not be assumed simply because weight or metabolic markers improve.
Some patients may experience improvements in menstrual regularity or other PMOS-related features as weight and metabolic health improve. However, these changes should not be interpreted as evidence that semaglutide directly treats ovarian dysfunction or acts as a fertility medicine.
4. Is Semaglutide Approved for PMOS? Setting Expectations
Semaglutide is not approved specifically for PMOS. The 2026 terminology change from PCOS to PMOS does not create a new drug indication.
When semaglutide is used in someone with PMOS, the relevant approved indication may be type 2 diabetes or weight management, depending on the individual medicine, formulation and regulatory approval. The presence of PMOS alone does not automatically make someone a candidate.
This distinction matters because semaglutide should not be presented as a cure for PMOS or as a dedicated treatment for fertility. PMOS care may involve lifestyle intervention, management of weight and metabolic risk, menstrual or androgen-related treatment, contraception where appropriate, and fertility treatment when pregnancy is desired.
There is also an important pregnancy consideration: semaglutide is not a fertility treatment, and anyone planning pregnancy should discuss its use and timing of discontinuation with their treating clinician.
5. Semaglutide and Fatty Liver Disease: A Major Recent Development
Fatty liver disease is now generally described using the term MASLD (metabolic dysfunction-associated steatotic liver disease). Its inflammatory form is called MASH (metabolic dysfunction-associated steatohepatitis). MASH can cause progressive liver injury and fibrosis and is clinically different from simple liver fat detected on an ultrasound.
Semaglutide’s role in MASH has moved beyond research into regulatory approval. In August 2025, the U.S. Food and Drug Administration approved Wegovy (semaglutide) for the treatment of MASH in adults with moderate-to-advanced liver fibrosis. In the phase 3 ESSENCE trial, 63% of participants receiving semaglutide had MASH resolution without worsening of fibrosis at week 72, compared with 34% receiving placebo. Improvement in liver fibrosis without worsening of MASH occurred in 37% of the semaglutide group versus 22% of the placebo group.
India has now followed with an important regulatory development. In July 2026, the Central Drugs Standard Control Organisation (CDSCO) approved Wegovy (semaglutide injection 2.4 mg) for non-cirrhotic MASH in adults with moderate-to-advanced liver fibrosis, to be used alongside a reduced-calorie diet and increased physical activity. This makes semaglutide a formally approved treatment option for a specific, higher-risk form of fatty liver disease in India.
This does not mean that everyone with fatty liver on an ultrasound should take semaglutide. The approved indication is specifically defined around MASH and liver fibrosis, and proper clinical assessment is required before treatment decisions are made.
6. What Semaglutide Does and Doesn’t Fix About Liver Health
Semaglutide can improve several factors associated with metabolic liver disease, including body weight, glycaemic control and metabolic health. In appropriately selected patients with MASH, clinical trial evidence has also demonstrated improvement in steatohepatitis and, in some patients, liver fibrosis.
But an important distinction is needed between reducing liver fat and treating established liver fibrosis. A person can have fatty liver without MASH, while another person may have MASH with significant fibrosis. These are not interchangeable diagnoses.
Semaglutide also does not replace assessment of alcohol-related liver disease, viral hepatitis, autoimmune liver disease, medication-related liver injury or other causes of abnormal liver tests. It is not a substitute for specialist assessment when advanced liver disease is suspected, and it is not a treatment for established decompensated cirrhosis.
Whether semaglutide is appropriate depends on the actual liver diagnosis, fibrosis stage, metabolic profile, other medicines and overall clinical picture. In some patients this may require assessment by a gastroenterologist or hepatologist alongside diabetes or obesity care.
7. Who With PMOS or Fatty Liver Might Be a Candidate
- Adults with PMOS who also meet appropriate criteria for an approved weight-management indication, particularly when excess weight is contributing to metabolic risk
- Adults with type 2 diabetes for whom semaglutide is appropriate under its diabetes indication and who also have PMOS or metabolic liver disease
- Adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis who meet the relevant semaglutide indication and are being assessed for treatment
- Patients with overlapping metabolic risk factors such as higher body weight, insulin resistance, prediabetes, type 2 diabetes or metabolic liver disease, where a comprehensive treatment plan may address several risks simultaneously
Having PMOS, insulin resistance or fatty liver alone does not automatically make someone a semaglutide candidate. Treatment depends on the specific indication, clinical history, contraindications, current medicines and individual risk-benefit assessment.
8. How This Fits Into TOTALL’s Broader Approach to Metabolic Disease
TOTALL approaches diabetes, obesity, endocrine disorders and metabolic conditions as interconnected parts of a patient’s overall health rather than as isolated diagnoses. That framework is particularly relevant when PMOS, insulin resistance, abnormal glucose regulation and fatty liver occur together.
For example, a patient with PMOS may also have excess weight and insulin resistance, while another patient may present primarily with abnormal liver enzymes or MASH and later be found to have broader metabolic risk. These situations require different diagnostic pathways, even when some of the underlying metabolic factors overlap.
Semaglutide can therefore be considered as one tool within a broader metabolic treatment plan, rather than as a single medicine intended to treat PMOS, fatty liver and insulin resistance independently.
9. What to Expect If You’re Being Considered for This
If semaglutide is being considered in the context of PMOS, metabolic risk or fatty liver disease, the assessment should go beyond simply asking whether you have one of these diagnoses.
Depending on the reason for treatment, your clinician may review body weight and waist circumference, blood glucose and HbA1c, lipid levels, blood pressure, liver enzymes and other metabolic markers. If PMOS is the primary concern, the assessment may also include menstrual history, androgen-related symptoms and other features relevant to the diagnosis.
If liver disease is the main concern, additional assessment may be needed to distinguish uncomplicated steatosis from MASH and determine the degree of fibrosis. This can involve non-invasive fibrosis scores, elastography or other imaging and, in selected cases, specialist hepatology assessment.
The goal is not simply to prescribe semaglutide because several conditions happen to coexist. The goal is to establish which problems are present, which are driving the patient’s risk, and where semaglutide fits alongside lifestyle treatment and other appropriate therapies.
10. Frequently Asked Questions
What is PMOS, and is it the same as PCOS?
Yes. Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name adopted in 2026 for the condition previously known as Polycystic Ovary Syndrome (PCOS). The name was changed to better reflect the condition’s broader endocrine, metabolic, reproductive and other health effects. The underlying condition and current clinical recommendations did not change simply because the name changed.
Can semaglutide help with PMOS?
Semaglutide is not approved specifically to treat PMOS. It may be considered when a person with PMOS also meets an approved indication for semaglutide, particularly weight management or type 2 diabetes. Improvements in weight and metabolic health may improve some PMOS-related features, but semaglutide should not be considered a dedicated PMOS or fertility treatment.
Is semaglutide approved for fatty liver disease in India?
Yes, for a specific form of fatty liver disease. In July 2026, CDSCO approved Wegovy (semaglutide 2.4 mg) for non-cirrhotic MASH in adults with moderate-to-advanced liver fibrosis, alongside a reduced-calorie diet and increased physical activity. This is different from saying that semaglutide is approved for every case of fatty liver detected on ultrasound.
Does semaglutide reverse insulin resistance?
Semaglutide can significantly improve insulin sensitivity and metabolic control, particularly through its effects on glucose regulation, appetite and body weight. However, insulin resistance has multiple causes and the degree of improvement varies between individuals. It is more accurate to say that semaglutide can improve insulin sensitivity than to describe it as permanently “reversing” insulin resistance.
Will semaglutide help me get pregnant if I have PMOS?
Semaglutide is not a fertility treatment and is not approved for improving fertility in PMOS. Some patients may experience more regular cycles as metabolic health and body weight improve, but this should not be interpreted as a direct fertility effect. Anyone actively planning pregnancy should discuss semaglutide with their clinician before conception.
Does everyone with fatty liver disease qualify for semaglutide?
No. The MASH indication is for a specific population with non-cirrhotic MASH and moderate-to-advanced liver fibrosis. A finding of fatty liver on ultrasound alone does not establish that diagnosis or automatically qualify someone for treatment.
Should I ask my doctor about semaglutide if I have insulin resistance but no diabetes?
It can be a reasonable discussion, particularly when insulin resistance occurs alongside excess weight or other metabolic risk factors. However, insulin resistance alone does not automatically create an indication for semaglutide. Your clinician should determine whether you meet an approved indication and whether the potential benefits outweigh the risks for you.
11. Conclusion
PMOS, fatty liver disease and insulin resistance are closely connected through a broader metabolic picture, although they remain distinct medical conditions that require individual assessment. The 2026 name change from PCOS to PMOS reflects the increasingly recognised endocrine and metabolic nature of the condition, rather than a change in how the disease is diagnosed or treated.
Semaglutide is not a cure for PMOS and is not a general-purpose treatment for every form of fatty liver. Its role is more specific: it can be used for approved diabetes or weight-management indications, and, following recent regulatory changes, semaglutide 2.4 mg also has an approved role in treating non-cirrhotic MASH with moderate-to-advanced liver fibrosis in the United States and India.
The most useful way to think about semaglutide in this setting is therefore not as a medicine for three separate conditions, but as one potential component of a properly assessed metabolic treatment plan.
For the full picture of how semaglutide works, dosage, side effects and brands, see our complete Semaglutide Guide. To discuss whether semaglutide is appropriate for PMOS, fatty liver disease or metabolic risk in your specific case, book a consultation with TOTALL’s diabetes and obesity specialists in Indore, or call +91 9302443344.
